MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'adverse event reporting'. Sat, 03 Sep 2011 02:38:08 +0100 http://www.medworm.com/index.php?rid=5140250&cid=t_128422_147_f&fid=39273&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FePharmaSummit%2F%7E3%2FFd53TmsH-k4%2Ftips-for-pharma-on-facebook.html Many Pharma companies are hesitant to use Facebook as a medium to communicate with their audience, and many fear it is because they will have additional worries concerning the FDA and adverse events of their drugs. Mashable recently set out and shared a few better ways for Pharma companies to communicate with their fans on Facebook while connecting with them at them at the same time. Some of the tips: - Know who is making the decisions about buying your product.  For example, doctors are not likely to reference Facebook when searching about a drug.  But for many Over the Counter drugs, consumers will look online and a Facebook page could be a great place to inform them about that drug. - Use the Facebook page as a way to communicate, connect and listen to your co... ePharma Summit blogs http://www.medworm.com/rss/comments.php?id=5140250 Fri, 12 Aug 2011 19:22:00 +0100 5140250 http://www.medworm.com/index.php?rid=4762766&cid=t_128422_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fshould-pharmaceutical-companies-get-involved-in-social-media%2F2011.04.28 Imagine you’re a pharmaceutical company product manager and your specific product helps people with a chronic illness, or a cancer that can be managed by taking a pill or an injectable medicine over many years. You want to be part of the dialogue patients have with each other. You want to be part of the community. Facebook users, and other social media participants, are increasingly forming groups around health conditions, big and small. You want to be there, because, after all, your company has invested hundreds of millions of dollars developing the approved drug and hopes this medicine, and perhaps a successor, will be on the market for a long time. This is an exciting time on the Internet and pharmaceutical product managers want to be part of health discussions. But it is fraught with... Better Health blogs http://www.medworm.com/rss/comments.php?id=4762766 Thu, 28 Apr 2011 21:00:44 +0100 4762766 http://www.medworm.com/index.php?rid=2513129&cid=t_128422_147_f&fid=38117&url=http%3A%2F%2Fwww.engageinhealth.com%2F2009%2F06%2Ftaking_a_proactive_approach_to.html One of pharma's biggest concerns with social media is adverse event (AE) reporting. But for an AE to be reportable, it must meet the four criteria: 1) an identifiable patient, 2) an identifiable reporter, 3) a suspect drug, and 4) the side effect. Most often online, #1 and #2 aren’t met. Last year, Nielsen even produced a report quantifying this. To handle AE reporting responsibly, companies that have created a presence in a social media property -- such as JnJ's Health YouTube Channel -- monitor their comments before posting in order to route any AEs appropriately. Some properties, like Facebook, don't allow for monitoring of comments before posting to the Wall, so companies may choose to turn off that feature. Not great for engaging with their audience, but it does avoid the risk. ... The Health Engagement Blog blogs http://www.medworm.com/rss/comments.php?id=2513129 Fri, 19 Jun 2009 21:10:13 +0100 2513129 http://www.medworm.com/index.php?rid=2381260&cid=t_128422_87_f&fid=36050&url=http%3A%2F%2Fwww.blisstree.com%2Fbreastfeeding123%2Fadverse-vaccine-reaction%2F My baby is sick. Possibly sick from the vaccine intended to protect her from illness. And I am sick at heart. You see, I took her in for her 9-month well baby visit three days ago. At that time, she received two vaccinations: DTaP and Rotavirus. Those of you really savvy about vaccinations might see the problem already. I didn’t realize it at the time, but the rotavirus vaccine is not recommended after the baby reaches the age of 32 weeks (about 8 months). RotaTeq rotavirus vaccineMy baby was overdue for her third and final dose of RotaTeq. I had put it off because we were on the waiting list for the Hib vaccine, which is in short supply and must be rationed out by pediatricians. In hindsight I realize I should have proceeded on schedule with my daughter’s other vaccinations, a... Breastfeeding 1-2-3 blogs http://www.medworm.com/rss/comments.php?id=2381260 Fri, 01 May 2009 05:12:48 +0100 2381260 http://www.medworm.com/index.php?rid=1509073&cid=t_128422_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F309593783%2F Consumers became the major source of adverse event reports to the FDA in 2006, replacing physicians, FDA News reports. In 1998, consumers reported 23,691 adverse events, compared with 48,314 physician reports. By 2006, a tipping point occurred - there were 127,475 consumer reports versus 113,444 physician reports, according to FDA data. And last year, the gulf grew wider - consumers reported 174,216 adverse events in 2007, which was 53,216 more than reported by docs, according to the data. Why the shift? FDA News speculates that consumers may have greater awareness of safety issues. That seems to be a reasonable assumption, given the headlines over antidepressants and Vioxx in 2004, a trend that continued last year with Avandia and Chantix. However, we would point out that safety issues ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1509073 Wed, 11 Jun 2008 12:32:24 +0100 1509073 http://www.medworm.com/index.php?rid=1426773&cid=t_128422_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F285334471%2F Where will the money go? Well, the agency says it will significantly expand its postmarketing safety activities, adopting new scientific approaches to drug safety to meet its commitments under the Prescription Drug User Fee Act, FDA News reports. The agency plans to spend fees to fund epidemiology “best practices” and data acquisition ($7 million in fiscal 2008, increasing to $9.5 million in fiscal 2012); new drug trade name review ($5.3 million in fiscal 2008, rising to $6.5 million in fiscal 2012); and risk management and communication ($4 million in fiscal 2008, rising to $5 million in fiscal 2012), according to FDA News. In a draft Drug Safety Five-Year Plan that the agency updates annually and issued for comment last Friday, the FDA signals its intention to use the fees t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1426773 Wed, 07 May 2008 11:56:21 +0100 1426773 http://www.medworm.com/index.php?rid=705917&cid=t_128422_132_f&fid=35011&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fmndoci%2F%7E3%2F129167024%2F I first started writing this post when L’Affaire Avandia first came to light, but decided to put it off this the incessant coverage had died down. Of course, days became weeks, but better late than never. I will not focus on the specifics of the Avandia situation, but rather on the concept of pharmacovigilance and the role of post-marketing analysis, at least as far as I understand the problem. Listening to a lot of talks on adverse event reporting at the DIA conference also definitely helped crystallize some of these thoughts. In the recent NEJM paper, Steve Nissen and Kathy Wolksi essentially carried out a meta analysis, where they combined results from multiple independent studies (42 clinical trials) to arrive at their conclusions. That got me thinking. What constitutes appropria... business|bytes|genes|molecules blogs http://www.medworm.com/rss/comments.php?id=705917 Sat, 30 Jun 2007 05:07:07 +0100 705917